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Available online 18 September 2014Wehave analyzed the cellular pathways andmetabolic adaptations that take place in primary
skin fibroblasts frompatientswithmutations in BCS1L, amajor genetic cause ofmitochondrial
complex III enzyme deficiency. Mutant fibroblasts exhibited low oxygen consumption rates
and intracellular ATP levels, indicating that the main altered molecular event probably is a
limited respiration-coupled ATP production through the OXPHOS system. Two-dimensional
DIGE and MALDI-TOF/TOFmass spectrometry analyses unambiguously identified 39 proteins
whose expression was significantly altered in complex III-deficient fibroblasts. Extensive
statistical and cluster analyses revealed a protein profile characteristic for the BCS1L mutant
fibroblasts that included alterations in energymetabolism, cell signaling and gene expression
regulation, cytoskeleton formation and maintenance, and intracellular stress responses. The
physiological validation of the predicted functional adaptations of human cultured fibroblasts
to complex III deficiency confirmed the up-regulation of glycolytic enzyme activities and the
accumulation of branched-chain among other amino acids, suggesting the activation of
anaerobic glycolysis and cellular catabolic states, in particular protein catabolism, together
with autophagy as adaptive responses to mitochondrial respiratory chain dysfunction and
ATP deficiency. Our data point to an overall metabolic and genetic reprogramming that could
contribute to explain the clinical manifestations of complex III deficiency in patients.
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39J O U R N A L O F P R O T E O M I C S 1 1 3 ( 2 0 1 5 ) 3 8 – 5 6remain poorly understood. We have investigated the molecular pathways and metabolic
adaptations that take place in primary skin fibroblasts from patients with mutations in the
BCS1L gene, a primary cause of mitochondrial complex III enzyme deficiency. Two-dimensional
DIGE together with MALDI-TOF/TOF mass spectrometry and physiological validation analyses
revealed a significant metabolic and genetic reprogramming as an adaptive response to
mitochondrial respiratory chain dysfunction. Our data provide information about specific
protein targets that regulate the transmitochondrial functional responses to complex III
deficiency, thereby opening new doors for future research.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria participate as key regulators of cellularmetabolism
in a large variety of physiological processes, and provide most of
the cellular energy (ATP) through the oxidative phosphorylation
(OXPHOS) system. The OXPHOS system is located in the
mitochondrial inner membrane and it is formed by five
multiprotein enzyme complexes that couple respiration and
ATP synthesis. Among these, respiratory chain cytochrome bc1
complex (or complex III) catalyzes the transfer of electrons from
reduced coenzyme Q to cytochrome c associated with proton
pumping to the intermembrane space [1]. The purified bovine
complex is an ~450 kDa symmetric homodimer [2,3]. Each
monomer is composed of three catalytic subunits (cyto-
chrome b, cytochrome c1 and the Rieske Iron–Sulfur Protein,
or RISP) and eight structural subunits of unknown function.
Isolated complex III enzyme deficiencies cause a broad
spectrum of symptoms that display tissue specificity in
humans [4]. They are caused by mutations in catalytic and
structural subunits as well as in assembly factors [5–10]. So
far, the vast majority of mutations leading to complex III
deficiency have been localized to the nuclear BCS1L gene,
which encodes a mitochondrial inner membrane translocase
necessary for the import and insertion of the RISP subunit into
complex III [11]. BCS1L mutations lead to three main clinical
phenotypes [12]: (1) Björnstad Syndrome, an autosomal reces-
sive disorder characterizedby sensorineural hearing loss and pili
torti [13]; (2) GRACILE Syndrome, a Finnish-heritage disease
caused by the homozygous p.Ser78Gly mutation [14], which is
characterized by fetal growth retardation, aminoaciduria, cho-
lestasis, iron overload, lactic acidosis, and early death; and
(3) complex III deficiency in neonates, infants or adults
presenting with liver disease and lactic acidosis, alone or in
combination with encephalopathy and visceral involvement
[6,15–21].
The pathophysiological mechanisms that contribute to the
clinical manifestations of BCS1L mutations remain poorly
understood. Mutations in BCS1L may lead to mitochondrial
complex III assembly and enzyme defects in patients with
Björnstad Syndrome or complex III deficiency [13,17,22], as
well as in late stages of GRACILE Syndrome in Bcs1l transgenic
mice [23]. This has been proposed to increase oxidative stress
through the production of reactive oxygen species (ROS) in a
mutation-dependent manner [13,22]. A study from our group
established a correlation between the severity of the clinical
manifestations of complex III deficiency and specific cellular
pathophysiological parameters in skin fibroblasts from six
patients harboring mutations in the BCS1L gene [22]. Cells
from patients with the most severe clinical phenotypesexhibited the slowest growth rates in glucose medium,
displayed severe enzyme deficiencies and assembly defects
of the respiratory chain complexes, increased ROS levels and
unbalanced expression of the cellular antioxidant defenses,
fragmented mitochondrial networks and increased cell death
rates [22]. In agreement, BCS1L knockdown in human cells
caused the disassembly of the mitochondrial supercomplexes
and led to morphological alterations of the mitochondrial
network [24]. On the contrary, Finnish patients with GRACILE
Syndrome exhibited normal complex III activity [14], and the
fact that BCS1L functions as a mitochondrial translocase
suggests that this protein could have broader functional
implications than complex III assembly. Iron overload is also
a common feature of patients with BCS1Lmutations leading to
GRACILE Syndrome or complex III deficiency, which suggests
an additional hypothetical role for BCS1L in iron metabolism
[14,16,25].
To further identify the mechanisms underlying complex III
deficiency, we have undertaken a combination of functional
studies and high-resolution differential proteomics in cultured
skin fibroblasts from four complex III-deficient patients harbor-
ing mutations in the BCS1L gene and four healthy controls.
Mutant fibroblasts showed significantly lower oxygen consump-
tion rates and intracellular ATP levels than controls. Subsequent
two-dimensional differential gel electrophoresis (2D-DIGE) and
MALDI-TOF/TOFmass spectrometry analyses revealed a protein
profile characteristic for the BCS1L mutant fibroblasts that
involved alterations in the energy metabolism, cytoskeleton
formation and maintenance, regulation of gene and protein
expression, cell signaling and the cellular stress responses.
Physiological validation analyses suggested the activation of
anaerobic glycolysis, cellular catabolism and autophagy asmain
adaptive responses to mitochondrial respiratory chain dysfunc-
tion and ATP deficiency. These data represent novel starting
points for elucidating the molecular mechanisms of complex III
deficiency.2. Material and methods
2.1. Fibroblast cultures
Primary skin fibroblasts from four patients and four healthy
donors (age and sex-matched) were cultured in 1 g/l glucose-
containing Dulbecco's modified Eagle's Medium (DMEM)
(Invitrogen) supplemented with 10% fetal bovine serum (FBS),
100 IU/ml penicillin and 100 IU/ml streptomycin at 37 °C and 5%
CO2. Mycoplasma testing was performed in fibroblasts by DAPI
staining and epifluorescencemicroscopy,which yieldednegative
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number (9–10 passages).
2.2. Cell respiration
Oxygen consumption inhuman fibroblastswasmeasuredusing
an XF24 Extracellular Flux Analyzer (Seahorse Bioscience). To
obtain ahomogeneousmonolayer of cells, around 5.0 × 104 cells
per well were plated the day before the experiment, depending
on the growth rate of each cell line, and in order to obtain about
15 μg protein per well on the day of the experiment. The cells
were then incubated for 1 h in unbufferedDMEMsupplemented
with 1 g/l glucose, 1 mM sodium pyruvate and 2 mMglutamine
at 37 °C in a CO2-free incubator. In all experiments, the protein
concentration in each well was determined using the Pierce
BCA Protein Assay Kit (Thermo Scientific) after cell lysis in RIPA
buffer (Sigma), and was used to calibrate the oxygen consump-
tion data.
2.3. ATP content measurements
Intracellular ATP was measured in fibroblasts grown in DMEM–
glucose culture medium using the ATP Bioluminescence Assay
Kit HS II (Roche) according to the manufacturer's instructions.
ATP concentrationwas calculated per 106 cells and expressed as
percentage of control cells' ATP concentration.
2.4. Protein extraction for DIGE analysis
Whole protein extractswere prepared for each cell line. Samples
were cleaned with the 2D Clean-up Kit (GE Healthcare) and
stored overnight in acetone at −20 °C. Pellets were resuspended
in 50 μl DIGE Buffer (10 mM Tris, 7 M urea, 2 M thiourea, 2%
CHAPS). Protein concentration was determined using the
Bradford reagent (BioRad).
2.5. DIGE experimental design and protein labeling
The proteomic comparison between whole protein extracts
from four controls (C) and four patient-derived (P) fibroblasts
was performed across four DIGE gels using the same pooled
sample internal standard (consisting on an equal mix of the
eight samples in the experiment) to reduce inter gel varia-
tions. This allows the straight comparison of all samples
regardless how the sample pairings were selected. Proteins in
each sample were fluorescently tagged with a set of matched
fluorescent dyes according to the manufacturer's protocol for
minimal labeling (GE Healthcare). To eliminate any dye-specific
labeling artifacts, two samples of each group (C and P) were
labeled with Cy3, and the other two were labeled with Cy5. The
pooled sample internal standard was always Cy2-labeled. In
every case, 400 pmol of dye was used for 50 μg of protein.
Briefly, labeling was performed for 30 min on ice in darkness,
and the reaction was quenched with 1 μl of 10 mM L-lysine for
10 min under the same conditions.
2.6. 2D electrophoresis and imaging of Cy-labeled proteins
The four pairs of Cy3- and Cy5-labeled samples (each contain-
ing 50 μg of protein) were combined and mixed with a 50 μgaliquot of the Cy2-labeled pooled standard. The mixtures
containing 150 μg of protein were diluted 1:1 with rehydration
buffer (7 M urea, 2 M thiourea, 4% CHAPS, 4% ampholytes
(pH 3–11), and 200 mM DTT). The IPG strips (24 cm, nonlinear
pH 3–11)were rehydrated overnightwith 450 μl of a rehydration
buffer as above but with 2% ampholytes, 0.002% bromophenol
blue, and 97 mM DeStreak reagent instead of DTT. The labeled
samples were then applied to the strips by cup loading on a
manifold equipped IPGphor II IEF system (GE Healthcare).
Isoelectric focusing was carried out for a total of 75 kVh using
the following conditions: 1 h at 120 V, 2 h at 500 V, gradient
from 500 V to 1000 V in 2 h, gradient from 1000 V to 5000 V in
6 h, and finally 10 h at 5000 V. Prior to the second dimension
run, the strips were equilibrated first for 12 min in equilibration
buffer (100 mM Tris–HCl (pH 8.0), 6 M urea, 30% glycerol, 2%
DTT and 2% SDS) and then for another 5 min in the same buffer
supplementedwith 2.5% iodoacetamide. The equilibrated strips
were transferred onto 12% homogeneous polyacrylamide gels
(2.6% C) cast in low fluorescence glass plates using an
Ettan-DALT six system (GE Healthcare). Electrophoresis was
run at 1 W/gel for about 18 h at 20 °C.
The differentially labeled co-resolvedproteinswithin each gel
were imaged at a resolution of 100 dots/in. using a Typhoon 9400
laser scanner (GEHealthcare). Cy2-, Cy3-, andCy5-labeled images
of each gel were acquired at excitation/emission values of 488/
520, 523/580, and 633/670 nm, respectively. Gels were scanned
directly between the glass plates, and the high resolution images
(pixel size 100 μm)were exported for data analysis. After imaging
for Cy dyes, the gelswere removed from the plates and subjected
to colloidal Coomassie staining.
2.7. DIGE data analysis
The DeCyder v6.5 software (GE Healthcare) was used for spot
detection and determination of quantity, inter gel matching,
and statistics. The differential in gel analysis (DIA) module was
used for automatic spot detection and abundance measure-
ments for each individual gel by comparing the normalized
volume ratio of each spot from a Cy3- or Cy5-labeled sample to
the corresponding Cy2 signal from the pooled sample internal
standard. The DIA data sets from each individual gel were
collectively analyzed using the biological variation analysis
(BVA) module, which allows inter gel matching and calculation
of average abundance for each protein spot among the four gels
of our study. Statistical significance was assessed for each
change in abundance using Student's t test and analysis of
variance analyses. We considered statistical significance to be
at the 95% confidence level (p < 0.05) when standardized
average spot volume ratios exceeded 1.2 in the four analyzed
gels (i.e. 12 analyzed images). Calculation of experimental
molecular weight and pI for each differential protein spot was
carried out using the PDQuest 7.3.1 computer software (BioRad).
Unsupervised principal component analysis (PCA), hierar-
chical clustering (HC), and k-means clustering analyses were
performed using the DeCyder extended data analysis module
on the group of spots identified as significantly changed.
These multivariate analyses clustered the individual Cy3-
and Cy5-labeled samples based on collective comparison of
expression patterns from the set of proteins. The groups of
protein expression characteristics are represented by each
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expression matrixes.
2.8. Mass spectrometry analysis
The gel spots of interest were manually excised from the gels
and transferred to microcentrifuge tubes. Samples selected
for analysis were washed twice with water, shrunk with 100%
ACN, and dried in a Savant SpeedVac. Then samples were
reduced with DTT, alkylated with iodoacetamide, and subse-
quently digested with 12.5 ng/μl sequencing grade trypsin
(Roche Applied Science) for at least 6 h at 37 °C. After digestion,
the supernatant was collected, and 1 μl was spotted onto a
MALDI target plate (384 spot Teflon®-coated plates) and
allowed to air dry at room temperature. Subsequently, 0.5 μl of
a 3 mg/ml solution of α-cyano-4-hydroxy-transcinnamic acid
matrix in 0.1%TFA and 50%ACNwas added to the dried peptide
digest spots and again allowed to air dry. The samples were
analyzed using the MALDI-TOF/TOF mass spectrometer 4800
Proteomics Analyzer and 4000 Series Explorer™ software
(Applied Biosystems). MALDI-TOF spectra were acquired in
reflector positive ionmode using 1000 laser shots per spectrum.
Data Explorer version 4.2 (Applied Biosystems) was used for
spectra analyses and generating peak picking lists. All mass
spectra were internally calibrated using autoproteolytic trypsin
fragments and externally calibrated using a standard peptide
mixture (Sigma Aldrich). TOF/TOF fragmentation spectra were
acquired by selecting the 10 most abundant ions of each
MALDI-TOF peptide mass map (excluding trypsin autolytic
peptides and other known background ions) and averaging
2000 laser shots per fragmentation spectrum. The parameters
used to analyze the datawere a signal to noise threshold of 20, a
minimum area of 100, and a resolution higher than 10,000 with
a mass accuracy of 20 ppm.
2.9. Online tools and database search
The monoisotopic peptide mass fingerprinting data obtained
from MS and the amino acid sequence tag obtained from each
peptide fragmentation inMS/MSanalyseswereused to search for
protein candidates using Mascot version 1.9 (Matrix Science).
Peak intensity was used to select up to 50 peaks per spot
for peptide mass fingerprinting and 50 peaks per precursor for
MS/MS identification. Tryptic autolytic fragment-, keratin-, and
matrix-derived peaks were removed from the data set used for
the database search. The searches for peptide mass fingerprints
and tandemMS spectrawere performed in the Swiss-Prot release
53.0 and TrEMBL release 37.0 databases without taxonomy
restriction, containing 269,293 and 4,672,908 sequence entries,
respectively, for each software version and database release.
Fixed and variable modifications were considered (Cys as
S-carbamidomethyl derivate and Met as oxidized methionine,
respectively), allowing one trypsin missed cleavage site and a
mass tolerance of 50 ppm. ForMS/MS identifications, a precursor
tolerance of 50 ppm and MS/MS fragment tolerance of 0.3 Da
were used. Identifications were accepted as positive when at
least five matching peptides and at least 20% of the peptide
coverage of the theoretical sequences matched within a mass
accuracy of 50 or 25 ppm with internal calibration. In every case
probability scores were significant at p < 0.01.Intracellular localization of the identified proteins was
predicted from the amino acid sequence using the PSORT II
software (http://psort.hgc.jp/form2.html). Mapping of proteins
identified by mass spectrometry, and database search onto
existing pathways and cellular networks was carried out using
theKEGG Pathway (http://www.genome.jp/kegg/pathway.html)
and STRING 9.1 (http://string-db.org/) Databases [26,27].
2.10. Western-blot analysis
The supernatants (corresponding to 10 μg of whole cell extracts)
were mixed with an equal volume of tricine sample buffer
(BioRad) containing 2% (v/v) 2-mercaptoethanol. The mixtures
were boiled for 5 min and proteins were separated on standard
10% SDS-PAGE gels and transferred onto PROTRAN™ nitrocellu-
lose membranes (Whatman®). Membranes were blocked in
phosphate-buffered saline (pH 7.4) containing 0.1% Tween-20
and 5% non-fat dried milk for at least 2 h at room temperature.
The blots were then hybridized with antibodies raised against
the following proteins: lamin-A/C (Santa Cruz), gelsolin (Abcam),
glyceraldehyde 3 phosphate dehydrogenase (Mitosciences), DJ-1
(Abcam) andβ-actin (Sigma). Peroxidase-conjugated anti-mouse
or anti-rabbit IgGs (Molecular Probes) were used as secondary
antibodies. Immunoreactive bands were detected by chemilu-
minescence with ECL® prime reagents (Amersham Biosciences)
in a G:Box Chemi IR6 Image Analyzer (Syngene). Quantitative
changes in band intensities were evaluated by densitometric
scanningwith the ImageJ software and the densitometric values
were normalized to those of the loading controls.
2.11. Indirect immunofluorescence
Cells were fixed with 4% paraformaldehyde for 15 min and
permeabilized for 15 min with 0.1% Triton X-100. Cells were
incubated in blocking buffer containing 10% goat serum for
1 h at room temperature. Immunodetection was performed
with the previously mentioned primary antibodies, and FITC
(MitoSciences) andAlexa 488 (Invitrogen)wereusedas secondary
antibodies. After appropriate rinsing, cover slips were mounted
in ProLong Gold antifade reagent (Molecular Probes) on glass
slides, and cells were viewedwith a Zeiss LSM 510Meta confocal
microscope and a 63× planapochromat objective.
2.12. Amino acid concentrations of cell culture media
Approximately 1.5 × 106 fibroblasts were plated and cultured
for 48 h in serum-free DMEM supplemented with 100 IU/ml
penicillin/streptomycin at 37 °C and 5% CO2. Cell culture media
were collected and the samples (200 μl) were deproteinized for
20 minwith 20 μl of 50% sulfosalicylic acid, centrifuged, and the
protein-free supernatant was mixed with a lithium citrate
buffer (1:1). Cationic exchange chromatography was performed
with a stepwise elution of free amino acids with citrate buffers
and detection with ninhydrin, using a Biochrom 30 amino acid
analyzer (Biochrom Ltd.) according to the manufacturer's
specifications. The amino acid concentrations were expressed
in μmol/l. The protein concentration on each sample was
determined with the Pierce BCA Protein Assay Kit (Thermo
Scientific) and used to normalize the amino acid concentration
data.
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity
was measured using a colorimetric GAPDH Assay Kit
(ScienCell™) and pyruvate dehydrogenase (PDH) activity was
determined using the PDH Enzyme Activity Dipstick Assay Kit
(Mitosciences), according to the manufacturer's protocols.
Enzyme activities were normalized by the protein concentra-
tion on each sample.
2.14. Data analysis
Unless indicated, all experiments were performed at least in
triplicate and results were presented as mean ± standard devi-
ation (SD) values. Statistical p values were obtained by applica-
tion of either Student's t test or Mann–Whitney U test using the
SPSS v15.0 program.Fig. 1 – Oxygen consumption, ATP levels and glycolytic flux
in complex III-deficient fibroblasts. (A) Real-time analysis of
oxygen consumption rates (OCR) in control (n = 4) and patients'
fibroblasts (n = 3) respiring in 1 g/l glucose-containingmedium.
Student's t test: ***(p < 0.001). (B) Intracellular ATP content in
control (n = 4) and patient's fibroblasts (n = 4) grown in 1 g/l
glucose-containing medium. Mann–Whitney U test: **(p < 0.01)
(C) Extracellular acidification rates (ECAR) as an indicator of
lactate release to the extracellular medium in control (n = 4)
and patient's fibroblasts (n = 3). All measurements were
performed at least six times per sample. Data are expressed
as percentages of the mean values obtained in controls ±
standard deviation.3. Results
3.1. Decreased oxygen consumption and ATP levels in
fibroblasts with mutations in BCS1L
To shed light on the metabolic alterations and signaling
pathways affected by mitochondrial respiratory chain
complex III enzyme deficiency, we first measured oxygen
consumption rates (OCR), intracellular ATP levels and
extracellular acidification rates (ECAR) in genetically and
biochemically characterized primary skin fibroblasts from
four healthy donors (C) and four complex III-deficient patients
(P) harboring mutations in the BCS1L gene [15,16,18,22]. Mea-
surements showed a significant reduction of ~30% in the oxygen
consumption rates (Fig. 1A) and a decrease of ~70% in the
intracellular ATP concentration (Fig. 1B) of BCS1L mutant
fibroblasts compared with the controls. No significant differ-
ences were observed in the extracellular acidification rates
between these two sample groups (Fig. 1C). The individual
values obtained for each patient's cell line are shown in
Supplemental Fig. 1.
3.2. 2D-DIGE analysis of fibroblasts with mutations in BCS1L
We next performed a 2D-DIGE proteomic analysis in whole
cell extracts from eight samples corresponding to four
controls and four fibroblasts with mutations in BCS1L (Fig. 2).
After four-plex 2D-DIGE, three individual images were obtain-
ed from each gel, corresponding to Cy2-, Cy3-, and Cy5-labeled
samples. The 12 gel images were analyzed using the DeCyder
software. DIA allowed the detection of an average of 1817 protein
spots on each image with a 2.73% coefficient of variation
between them. Then inter image spot matching was carried out
byBVA. In this step, anaverage of 1456 spotswasmatchedon the
gels (2.71% coefficient of variation), and their average abun-
dances among the 12 images of our study were calculated. We
considered changes within a 95% confidence interval (p < 0.05)
and standardized average spot volume ratios exceeding 1.2 in the
four analyzed gels. This analysis yielded a total of 52 protein
species common to the 12 gel images that were unambiguously
identified as significantly altered in complex III deficiency: 34
spots were significantly and reproducibly increased in all fourpatients' fibroblasts relative to the four controls, and 18 spots
were decreased. These 52 spots are depicted on a representative
DIGE gel image shown in Fig. 3.
Fig. 2 – DIGE experimental design. Fibroblasts were obtained from age and sex-matched control individuals (C1–C4) and complex
III-deficient patients (P1–P4). Cells were balanced for passage number and homogenized prior to protein extraction. Whole cell
extracts were purified and labeled with the corresponding Cy dyes. Samples were thenmixed and resolved on four independent
DIGE gels. Three fluorescence imageswere obtained from each gel and subjected to image analysis using DeCyder software. After
biological variation analysis, spots that exhibited significant quantity modifications in patients' fibroblasts were identified by
MALDI-TOF/TOFmass spectrometry. Finally, extended data analysis (EDA) andKEGG and STRINGdatabase searcheswere carried
out to gain further information about protein alterations that are inherent to complex III deficiency.
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complex III-deficient fibroblasts
For the identification of proteins, spots were selected,
digested in gel, and analyzed by MALDI-PMF-MS. A Mascot
database search using the PMF spectra allowed the identifica-
tion of the proteins present in 39 out of the 52 spots obtained
fromduplicate gels (spots 7, 12, 29, 33, 35, 38, 40, 46, 47, 48, 49, 50
and 51 failed to be identified). In nine cases (spots 2, 9, 15, 21, 23,
24, 32, 39 and 52), two different proteins were identified on the
same spot, and we also detected 16 redundancies because
of posttranslational modifications or proteolysis. The last 7
proteins from the group of 52 were identified by tandem MS.
Altogether 39 different proteins were identified as altered in
BCS1L-associated complex III deficiency, as listed in Table 1 and
Supplemental Table S1 with detailed information comprising
experimental and theoretical molecular weight and pI values,
accession number, and identification parameters.
3.4. Multivariate statistical analysis
We sought to establish biological significance of the
protein changes by performing multivariate statistical tests
on the proteins identified by DIGE-MS. As shown in Fig. 4A,principal component analysis displayed a good separation of
the control and patients' sample groups. For the 52 protein
spots altered in the DIGE analysis, the first principal
component (PC1) distinguished 73.9% of the variance, and
an additional 10.6% variation was distinguished by the
second principal component (PC2). A second type of pattern
analysis, the k-means algorithm, was carried out on these 52
protein forms. This analysis clustered them into four groups
displaying similar patterns (Fig. 4B). The proteins in each
k-means cluster are listed in Supplemental Table S2. Finally,
hierarchical clustering analysis (Fig. 4C) established two
different patterns in this group of proteins and clearly differ-
entiated these two diverse profiles, clustering patients-
derived (marked within a green square in Fig. 4C) and control
fibroblasts (orange square). Protein spot numbering indicated
in the heat map correlates with the information shown in
Table 1.
The variations in the expression levels of some of the
proteins altered in the complex III deficient-fibroblasts were
validated using Western-blot and immunofluorescence analy-
ses (Fig. 5). These analyses confirmeddecreased levelsof nuclear
lamin-A/C, and increased levels of cytoplasmic gelsolin,
Fig. 3 – Representative Cy2-labeled internal standard proteomemap indicating the proteins altered in complex III-deficient
fibroblasts. Proteins were resolved in a 3–11 (nonlinear) pH range on the first dimension and on 12% acrylamide gels on the
second dimension. Proteins that exhibited significant expression alterations in patients' samples were identified by
MALDI-TOF or MALDI-TOF/TOF mass spectrometry. These proteins are listed in Table 1 by the same number as that in the
figure.
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endoplasmic reticulum DJ-1 protein in the BCS1L mutant
fibroblasts compared with the controls.
3.5. Cellular pathways altered in complex III-deficient fibroblasts
A database search was carried out to analyze the predicted
subcellular localization of these proteins and to assign them
into different functional groups. Most of the identified proteins
were predicted as mainly cytosolic (69%), with an additional
15% being predicted as nuclear, 8% associated with other
membrane structures or located in other subcellular organelles,
such as the endoplasmic reticulum, vacuoles, or peroxisomes,
and only 8% being predicted as purely mitochondrial.
Bioinformatics analysis using the KEGG Pathway and
STRING 9.05 Databases [26,27] enabled the characterization of
biological association networks related to these differentially
expressed proteins that allowed us to identify the biochemical
pathways that could be altered in complex III deficiency.
According to their specific cellular roles, the 39 proteins whose
expression was altered in the BCS1L mutant fibroblasts were
divided into five different functional categories. The main
protein group (31%) is involved in metabolic pathways that
primarily regulate energy metabolism (specifically affecting
glycolysis, the TCA cycle and the pentose phosphate andhexosamine pathways) and iron homeostasis. The remainder
proteins are involved either in the regulation of gene
expression at the levels of transcription, DNA replication or
protein synthesis (23%), are structural or cytoskeleton-
related (23%), take part in intracellular transport events and
cell signaling (13%), or are either chaperones or regulatory
proteins involved in cellular responses to metabolic and
oxidative stress (10%).
We next aimed to physiologically validate some of the
predicted functional adaptations of human cultured fibroblasts
to mitochondrial complex III deficiency. Our DIGE analysis
showed increased levels of two enzymes involved in the
glycolytic pathway, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and α-enolase, suggesting the up-regulation of glycol-
ysis as a way to produce ATP when the respiratory chain is
malfunctioning. Triplicate spectrophotometric measurements
revealed an increase of ~52% in the mean GAPDH enzyme
activity of fibroblasts with mutations in BCS1L compared with
that of the controls, suggestive of an up-regulation of the
glycolytic flux (Fig. 6A). Proteomics also revealed decreased
levels of dihydrolipoyl dehydrogenase (DLD) in the BCS1Lmutant
fibroblasts. DLD is an enzyme involved in the mitochondrial
glycine cleavage system, which is also a key component of the
pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase,
and branched-chain alpha-ketoacid dehydrogenase complexes,
Table 1 – Proteins identified by 2-D DIGE-MS as differentially expressed in complex III-deficient fibroblasts grouped according to their predicted biological function.
Spot
no.
Gene
IDa
Swiss-Prot a Protein name Av.
ratio b
t test Cellular role Loc. c Scored No. pept./number
of mass valuese
Cov.
(%) f
Metabolism
3 MTHFD1 P11586 C-1-tetrahydrofolate synthase −1.53 0.013 One-carbon metabolism; Tetrahydrofolate
interconversion
Cyt 176 25/65 31
9 mix H6PD O95479 Hexose-6-phosphate dehydrogenase −1.24 0.037 Pentose phosphate pathway Cyt/ER 62 12/65 17
17 ENO1 P06733 Alpha-enolase 1.3 0.03 Glycolysis Cyt 104 15/65 37
23 mix DLD P09622 Dihydrolipoyl dehydrogenase −1.35 0.036 Pyruvate decarboxylation; TCA cycle;
Mitochondrial glycine cleavage system
Mit 70 NLGLEELGIELDPR.G (46) 7
23 mix G6PD P11413 Glucose-6-phosphate 1-dehydrogenase −1.35 0.036 Pentose phosphate pathway Cyt 58 NSYVAGQYDDAASYQ
R.L (43)
6
25 DLST P36957 Dihydrolipoyl lysine-residue
succinyltransferase
−1.63 0.019 TCA cycle Mit 154 16/34 31
30 ALDOA P04075 Fructose-bisphosphate aldolase A −1.79 0.04 Glycolysis Cyt 144 17/65 59
32 mix GAPDH P04406 Glyceraldehyde-3-phosphate
dehydrogenase
1.86 0.031 Glycolysis Cyt 122 17/59 50
36 GNPDA1 P46926 Glucosamine-6-phosphate isomerase 1 1.51 0.012 Aminosugars metabolism Cyt 82 12/51 38
39 mix PGLS O95336 6-Phospho gluconolactonase 1.55 0.0064 Pentose phosphate pathway Cyt 133 WTLGFCDER.L (9) LLTVP
FEKHSTL.- (29)
IVAPISDSPKPPPQR.V (37)
36
43 APRT P07741 Adenine phosphoribosyl transferase 1.33 0.037 AMP formation via purine ribonucleoside
salvage
Cyt 99 9/39 57
45 FTL P02792 Ferritin light chain 2.2 0.021 Iron homeostasis Cyt 82 9/31 46
Regulation of gene expression
2 mix SND1 Q7KZF4 Staphylococcal nuclease
domain-containing protein 1
−1.32 0.036 Transcriptional coactivator Nuc 187 26/65 32
9 mix DDX1 Q92499 ATP-dependent RNA helicase DDX1 −1.24 0.037 Transcriptional coactivator; mRNA
processing
Nuc 207 28/65 45
13 XRCC6 P12956 X-ray repair cross-complementing
protein 6
−1.48 0.018 Involved in DNA non-homologous end
joining, required for double-strand break
repair and DNA somatic recombination
Nuc 72 13/65 24
14 XRCC6 P12956 X-ray repair cross-complementing
protein 6
−2.11 0.0034 Involved in DNA non-homologous end
joining, required for double-strand break
repair and DNA somatic recombination
Nuc 106 13/32 23
18 SYNCRIP O60506 Heterogeneous nuclear
ribonucleoprotein Q (hnRNP Q)
1.26 0.024 mRNA processing and stability mechanisms Nuc 168 23/56 33
19 LMNA P02545 Lamin-A/C −1.65 0.028 Nuclear lamina component; Involved in
nuclear membrane architecture, chromatin
organization, and telomere dynamics
Nuc 158 TALINSTGEEVAMR.K (13)
VAVEEVDEEGKFVR.L (70)
NSNLVGAAHEELQQSR.I (43)
15
21 mix NARS O43776 Asparagine-tRNA ligase 2.18 0.0067 tRNA aminoacylation for protein
translation
Cyt 80 13/65 29
31 EIF3H O15372 Eukaryotic translation
initiation factor 3 subunit H
−1.22 0.017 Protein synthesis Cyt 76 12
(continued on next page)
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(continued)
Spot
no.
Gene
IDa
Swiss-Prot a Protein name Av.
ratio b
t test Cellular role Loc. c Scored No. pept./number
of mass valuese
Cov.
(%) f
LFKPPQPPAR.M (6) GEPPL
PEEDLSK.L (25) QSRGEPPL
PEEDLSK.L (20)
42 ABHD14B Q96IU4 Alpha/beta hydrolase
domain-containing protein 14B
1.35 0.035 Putative transcriptional activator Nuc 68 6/17 34
52 mix SSBP1 Q04837 Mitochondrial single-stranded
DNA-binding protein (mtSSB)
3.83 0.047 Mitochondrial DNA replication Mit 93 12/65 61
Cytoskeleton formation and maintenance
1 VCL P18206 Vinculin −1.42 0.041 Actin cytoskeleton; Cell-matrix and
cell–cell adhesion
Cyt/PM 264 42/65 37
4 GSN P06396 Gelsolin 2.97 0.017 Assembly/disassembly of actin filaments Cyt 73 13/65 18
5 GSN P06396 Gelsolin 1.95 0.023 Assembly/disassembly of actin filaments Cyt 106 17/65 24
6 GSN P06396 Gelsolin 1.92 0.032 Assembly/disassembly of actin filaments Cyt 77 12/48 16
8 GSN P06396 Gelsolin 3.39 0.042 Assembly/disassembly of actin filaments Cyt 61 12/60 17
10 MSN P26038 Moesin −1.47 0.032 Connections between plasma membranes
and actin-based cytoskeletons
Cyt/PM 158 26/53 31
11 MSN P26038 Moesin −1.52 0.011 Connections between plasma membranes
and actin-based cytoskeletons
Cyt/PM 116 25/65 30
20 WDR1 O75083 WD-repeat containing
protein 1
−1.54 0.014 Disassembly of actin filaments Cyt 103 9/15 16
21 mix DPYSL2 Q16555 Dihydropyrimidinase-related
protein 2 (CRMP-2)
2.18 0.0067 Cytoskeleton remodeling Cyt 83 13/65 35
22 DPYSL2 Q16555 Dihydropyrimidinase-related
protein 2 (CRMP-2)
2.92 0.037 Cytoskeleton remodeling Cyt 189 25/65 52
24 mix VIM P08670 Vimentin −1.33 0.03 Intermediate filaments component Cyt 238 26/65 58
24 mix TUBA1B P68363 Tubulin alpha-1B chain −1.33 0.03 Microtubules constituent Cyt 197 22/65 50
26 ARHGAP1 Q07960 Rho GTPase-activating
protein 1 (p50RhoGAP/
CDC42GAP)
1.2 0.028 Rho protein mediated signal transduction;
Actin cytoskeleton remodeling
Cyt/PM 108 15/65 33
27 SEPT11 Q9NVA2 Septin-11 1.39 0.029 Filament-forming cytoskeletal GTPase Cyt 200 21/45 38
Intracellular trafficking and signal transduction
2 mix SEC24D O94855 Protein transport protein
SEC24D
−1.32 0.036 Anterograde protein transport from ER
to Golgi
Cyt 67 18/65 17
28 SNX6 Q9UNH7 Sorting nexin-6 1.2 0.036 Retrograde protein transport from
endosomes to the trans-Golgi network
Cyt 191 25/65 50
32 mix ANXA2 P07355 Annexin A2 1.86 0.031 Endosomes sorting Cyt/ECM 153 19/59 53
34 ANXA2 P07355 Annexin A2 2.06 0.044 Endosomes sorting Cyt/ECM 211 20/35 45
37 ANXA4 P09525 Annexin A4 1.71 0.041 NF-kappaB signaling pathway; Possibly
involved in exocytosis
Cyt 366 39/65 73
44 PEBP1 P30086 Phosphatidyl ethanolamine-binding
protein 1 (PEBP1/RKIP)
1.2 0.033 Serine protease inhibitor; Inhibits
MAP kinase cascade
Cyt 158 14/65 64
52 mix PEBP1 P30086 Phosphatidyl ethanolamine-binding
protein 1 (PEBP1/RKIP)
3.83 0.047 Serine protease inhibitor; Inhibits
MAP kinase cascade
Cyt 90 9/65 54
Table 1 (continued)
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Cellular stress responses
15 mix PDIA4 P13667 Protein disulfide-isomerase
A4 (ERP70)
1.67 0.05 Processing and folding of secretory
proteins in the ER
ER 67 13/65 19
15 mix HSPA5 P11021 78 kDa glucose-regulated
protein (GRP78)
1.67 0.05 Required for ER integrity and
stress-induced autophagy
ER 309 35/65 47
16 HSPA5 P11021 78 kDa glucose-regulated
protein (GRP78)
2.03 0.034 Unfolded protein response; Required for
ER integrity and stress-induced autophagy
ER 418 41/65 55
39 mix ERP29 P30040 Endoplasmic reticulum
resident protein 29 (ERP29)
1.55 0.0064 Processing and folding of secretory
proteins in the ER
ER 64 ILDQGEDFPASEMTR.I
(31)
26
41 PARK7 Q99497 DJ-1 1.54 0.003 Redox sensor; Protects cells against
oxidative stress;
Transcriptional regulator; Maintenance
of mitochondrial network morphology
and mitophagy
Cyt/Mit/Nuc 86 10/21 43
Cyt, cytoplasmic; Nuc, nuclear; ER, endoplasmic reticulum; Mit, mitochondrial; ECM, extracellular matrix; PM, plasma membrane.
The first column (No.) indicates the protein spot numbers according to Fig. 3. Each spot was common to the total number (12) of gel images obtained in this analysis.
a Gene and protein identities and accession numbers according to GenBank and Uniprot/Swiss-Prot/TrEMBL databases, respectively.
b Average volume ratio OA/N quantified by DeCyder BVA module.
c Subcellular localization according to Uniprot database and PSORT information.
d Mascot MS protein score, or MS/MS ion score, obtained from MALDI-TOF/TOF spectra. In all cases, a probability score <0.01 was obtained.
e Number of peptide masses matching the top hit from MS-Fit PMF/number of peptide masses searched. On each spot, the 65 most intense peaks were launched for search. When peptide sequence
appears, the fragmentation ions score is indicated between brackets.
f Amino acid sequence coverage for the identified proteins.
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Fig. 4 – Unsupervised multivariate analysis of the DIGE assay. (A) Principal component analysis clustered the 8 individual
Cy3- and Cy5-labeled expression maps into control (orange) or patients' (green) groups differentiated by two principal
components that distinguish the variance. (B) k-Means cluster analysis showing the four different clusters that group the
identified proteins. q, cluster quality; no, number of proteins belonging to each cluster. The set of proteins corresponding to
each cluster is listed in Supplemental Table S2. (C) Unsupervised hierarchical clustering of the 8 independent images based
on the global expression patterns of the 52 protein spots that were altered in complex III-deficient fibroblasts. Clustering of
individual samples is shownon topwith theDIGEgel number and typeofdye labeling for eachsample listedat thebottom.Clustering
of individual proteins is shown on the left with relative expression values displayed as an expression matrix (heat map) using a
standardized log abundance scale ranging from negative values (green) to positive values (red), and the spot numbers are listed
along the right side. These numbers are in agreementwith those listed in Table 1. ↑P and ↓P, proteinswhose expression is up- and
down-regulated, respectively.
48 J O U R N A L O F P R O T E O M I C S 1 1 3 ( 2 0 1 5 ) 3 8 – 5 6therefore playing crucial roles in key steps of the intermediary
metabolism. Defects in DLD are involved in the development
of maple syrup urine disease (MSUD) [OMIM: 248600], a
metabolic disorder caused by an enzyme defect in the
catabolic pathway of the branched-chain amino acids,
which accumulate together with their corresponding ketoacids, leading to encephalopathy and progressive neuro-
degeneration [28]. As expected, the decreased DLD protein
levels provoked a decrease of ~43% in the mean PDH enzyme
activity of patients' fibroblasts compared with the controls
(Fig. 6B). We next analyzed whether the reduced DLD levels
in BCS1L mutant fibroblasts also led to the accumulation of
Fig. 5 – DIGE assay validation. (A) Western-blot analysis of differentially-expressed proteins in BCS1Lmutant fibroblasts. 10 μg
of whole cell protein lysates were separated on 10% SDS-PAGE gels, blotted into nitrocellulose membranes and incubated with the
indicated antibodies. (B) Quantitative changes in band intensities were evaluated by densitometric scanning with the ImageJ
software. Signals from at least three independent experiments per sample were quantified; the densitometric mean values of the
patients' fibroblasts (n = 4)werenormalized to thoseof the loading controlβ-actin, and expressed aspercentages of themean control
values (n = 4, horizontal bar) ± standard deviation. (a.d.u.), arbitrary densitometric units. (C) For the detection of the indicated
proteins, indirect immunofluorescence was performed at least in duplicate per sample in fixed controls (n = 3) and patients'
fibroblasts (n = 4). A representative image is shown.
49J O U R N A L O F P R O T E O M I C S 1 1 3 ( 2 0 1 5 ) 3 8 – 5 6its reaction precursors, such as glycine or branched-chain
amino acids. Cells were grown for 48 h in serum-free
medium, and the amino acid concentrations from cell culture
media were measured in triplicate (Fig. 6C). A prominent
increase in the concentration of the branched-chain amino
acids leucine, isoleucine, and valine was observed in patients'fibroblasts compared with the controls, together with raised
levels of other amino acids, such as glutamine, threonine,
glycine, serine, cysteine, methionine, tyrosine, phenylalanine,
lysine, histidine, tryptophan and arginine. These data support
the alteration of branched-chain amino acid catabolism prob-
ably as a consequence of the DLD defect, although the
Fig. 6 – Physiological validation of putative functional adaptations of human fibroblasts to mitochondrial respiratory chain complex
III enzyme deficiency. Glycolysis up-regulation was assessed by enzymatic measurements of (A) cytosolic GAPDH and (B)
mitochondrial PDH activities in the BCS1Lmutant fibroblasts (n = 4) and controls (n = 4). Data are expressed as the mean values of
three independent measurements per sample ± standard deviation. (a.d.u.), arbitrary densitometric units. (C) Amino acid
concentrations of serum-free cell culture media from control and BCS1Lmutant fibroblasts. To determine the amino acid
concentrations, cationic exchange chromatography was performed in triplicate per sample. Data are expressed as the mean
values obtained from controls (n = 4) and from the four patients' fibroblasts ± standard deviation.
50 J O U R N A L O F P R O T E O M I C S 1 1 3 ( 2 0 1 5 ) 3 8 – 5 6increased levels of most amino acids could be indicative of
a general activation of protein catabolism in complex
III-deficient fibroblasts. Based in the results obtained from
the DIGE and validation analyses, a hypothetical model of
the physiological adaptations that take place in fibroblasts
with mutations in BCS1L is proposed in Fig. 7.4. Discussion
In this work we have analyzed the cellular and metabolic
adaptations that take place in primary skin fibroblasts from
patients with mitochondrial complex III deficiency. To identify
these mechanisms, we undertook a high-resolution differen-
tial proteomic analysis of cultured skin fibroblasts from four
complex III-deficient patients harboring diversemutations in
the BCS1L gene and four healthy controls. This experimental
strategy yielded a total of 39 proteins successfully identified bymass spectrometry that were differentially expressed between
control and patients' samples. The protein profile characteristic
for BCS1L-associated complex III deficiency suggested alter-
ations in pathways controlling energy metabolism and cellular
homeostasis, cytoskeleton formation and maintenance, gene
expression and protein synthesis, intracellular transport and
signal transduction, and cell stress responses.4.1. Metabolic alterations
The main protein group whose expression was altered in the
BCS1Lmutant fibroblasts was involved in energy metabolism.
In complex III-deficient fibroblasts the main altered molecular
event is probably a limited respiration-coupled ATP production
through the OXPHOS system, which would force a metabolic
switch that would enable to obtain energy primarily from
glycolysis and alternative catabolic processes, with a parallel
reductionor blockage of alternative glucose- andATP-consuming
Fig. 7 – Hypothetical model of the functional adaptations of human fibroblasts to mitochondrial respiratory chain complex III
enzyme deficiency. Mutations in the BCS1L assembly factor cause severe complex III enzyme deficiency, which hampers
oxygen consumption and ATP synthesis. A metabolic switch towards glycolysis and protein catabolism probably occurs in an
attempt to maintain the intracellular ATP levels, increasing the ATP productive phase of glycolysis (1, 2 and 3) and decreasing
the pyruvate dehydrogenase and Krebs cycle activities (4, 5). These events would lead to the accumulation of intermediate
metabolites and amino acids (5, 6). A blockage of the pentose phosphate pathway (7, 8) could also be inferred, which would
affect the synthesis of purines and pyrimidines and therefore nucleic/ribonucleic acid formation, resulting in an increased
AMP/ATP ratio (9, 10). The detoxifying glutathione metabolism would also be affected, which would amplify ROS damage (11).
Eventually, the degradation of extracellular matrix components could take place as an alternative way to obtain energy (12), as
well as alterations in the iron homeostasis (13) and the breakdown of the cytoskeleton architecture (14). These events could
lead to alterations in the regulation of gene expression (15, 16 and 17), in intracellular trafficking and signal transduction
mechanisms (18), as well as provoke a raise in the cellular responses to the oxidative andmetabolic stress (19). Proteins whose
levels were increased in the BCS1L mutant fibroblasts compared to the controls are indicated in red, and those whose levels
were decreased are shown in green. Abbreviations are in accordance with the gene identity of proteins listed in Table 1.
51J O U R N A L O F P R O T E O M I C S 1 1 3 ( 2 0 1 5 ) 3 8 – 5 6pathways, such as the phosphate pentose and hexosamine
pathways, and a decreased TCA cycle.
During glycolysis, glucose is converted into pyruvate and
the free energy released is used to form the energy-rich
molecules ATP and NADH. In fibroblasts with BCS1L muta-
tions this pathway is affected at the levels of three enzymes,
presenting reduced levels of fructose-bisphosphate aldolase A
(ALDOA), and increased levels of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and α-enolase. ALDOA catalyzes the
reversible conversion of fructose 1,6-bisphosphate into glycer-
aldehyde 3-phosphate (G3P) and dihydroxyacetone phosphate
(DHAP). Since ATP is required for the synthesis of fructose1,6-bisphosphate in the first steps of glycolysis, it is possible
that the reduced ALDOA levels are a consequence of the limited
availability of its substrate. This would imply reduced levels of
G3P andDHAP,which are necessary substrates for the glycolytic
energy generation phase inwhichATP andNADHare produced.
The first step of this second phase of glycolysis is catalyzed by
GAPDH, which converts G3P into D-glycerate 1,3-bisphosphate.
α-Enolase is responsible for thepenultimate step of glycolysis in
which the catalysis of 2-phosphoglycerate to phosphoenol
pyruvate takes place. Therefore, the increased levels of GAPDH
and α-enolase could take place as compensatory responses to
increase the glycolytic flux efficiency and pyruvate biosynthesis,
52 J O U R N A L O F P R O T E O M I C S 1 1 3 ( 2 0 1 5 ) 3 8 – 5 6which in aerobic conditions is transformed through the pyruvate
dehydrogenase complex into acetyl-CoA, usable in the mito-
chondrial TCA cycle to carry out cellular respiration and ATP
production. However, in fibroblasts with mutations in BCS1L
anaerobic glycolysis would not increase enough to compensate
for a deficient oxidative phosphorylation, since ATP levels
remained significantly lower in the patients' fibroblasts com-
pared with controls.
Ourproteomic analysis suggestedalterations inbothpyruvate
conversion and the TCA cycle activities due to reduced levels of
two key mitochondrial enzymes: dihydrolipoyl dehydrogenase
(DLD) and dihydrolipoyl lysine-residue succinyltransferase
(DLST). DLD is a multifunctional enzyme that catalyzes NADH
oxidation and plays an important role in redox metabolism
[29,30]. DLD is a functional component of the pyruvate dehydro-
genase complex, thus decreasing its levels could compromise
the conversion of pyruvate into acetyl-CoA and lead to the
accumulation of cytosolic pyruvate, which is probably trans-
formed by the enzyme lactate dehydrogenase into lactate and
NAD+ to keep glycolysis active. The fact that BCS1L mutant
fibroblasts didnot generally present increasedacidificationof cell
culturemedia suggests that, despite glycolysis up-regulation, the
accumulating pyruvate could undergo a rapid transamina-
tion to alanine in order to avoid environmental acidification.
Besides, DLD is a component of the branched-chain α-ketoacid
dehydrogenase complex (BCKDC), involved in the catabolism
of branched-chain amino acids and their derivatives. Reduced
DLD levels could therefore explain the accumulation of
branched-chain amino acids observed in fibroblasts with
mutations in BCS1L, although the general increase in amino
acid levelsmight be indicative of a broader activation of protein
catabolism. Both DLD and DLST are also components of the
oxoglutarate dehydrogenase complex, which catalyzes the
conversion of α-ketoglutarate to succinyl-CoA in the TCA
cycle. Therefore, the decreased DLD and DLST levels could
presumably compromise the normal flux and favor the
accumulation of intermediate metabolites of the TCA cycle. In
agreementwith our results, the livermetabolomic profile of late
disease stages of GRACILE Syndrome in transgenic mice
showed decreased levels of G3P and DHAP, decreased activities
and accumulation of intermediate metabolites of the TCA
cycle, and increased levels of amino acids and long-chain
acylcarnitines [31].
According to our data, the phosphate pentose (PP) pathway
would also be down-regulated in favor of glycolysis, since
both routes require glucose oxidation in their initial steps.
There are two distinct phases in the PP pathway, the oxidative
phase, in which most of the cellular reducing energy in form
of NADPH is generated, and the non-oxidative phase, in which
5-carbon sugars are synthesized for nucleotide and nucleic
acid biogenesis. The BCS1L mutant fibroblasts showed de-
creased levels of two initial PP pathway rate-limiting en-
zymes: glucose-6-phosphate dehydrogenase (G6PDH) and
hexose-6-phosphate dehydrogenase (H6PD). G6PDH converts
glucose-6-phosphate into 6-phosphoglucono-δ-lactone whilst
reducing NADP+ to NADPH. NADPH is necessary for lipid and
nucleic acid biosynthesis, and it is used by the glutathione
reductase enzyme to reduce glutathione, which is in turn
oxidized by glutathione peroxidase to convert reactive hydro-
gen peroxide (H2O2) into H2O. Therefore, NADPH re-oxidationconstitutes an essential step to prevent the accumulation of
hydroxyl free radicals and to ensure protection against oxida-
tive damage. It is reasonable to expect that decreased G6PDH
levels may hinder H2O2 detoxification by cutting the NADPH
supply, which would explain the high H2O2 levels and the
alterations in the cellular antioxidant defenses previously
observed in fibroblasts with mutations in BCS1L [22]. H6PD is
the initial component of the PPpathway inside the endoplasmic
reticulum (ER) that generates NADPH for ER enzymes, and its
blockage may activate the cellular stress response known as
unfolded protein response (UPR) [32], in agreement with the up
regulation of theUPRproteinsGRP78, ERP29 andERP70 observed
in the mutant fibroblasts (see ahead). The presumed reduction
in the levels of the G6PDH and H6PD reaction products could
potentially provoke a compensatory raise in the levels of the
second enzyme of the PP pathway, 6-phosphogluconolactonase
(PGLS), as revealed by our DIGE analysis.
As a consequence to the partial blockage of the PP pathway,
lipids as well as nucleic acid biosynthesis would be hampered.
Accordingly, reduced levels of C-1-tetrahydrofolate synthase
were detected. This enzyme participates in the synthesis of
tetrahydrofolate derivatives, essential cofactors used in amino
acid metabolism and for the synthesis of purines and pyrimi-
dines. The BCS1Lmutant fibroblasts also showed increased levels
of adenine phosphoribosyltransferase (APRT) and glucosamine-
6-phosphate isomerase 1 (GNPDA1). APRT catalyzes the forma-
tion of AMP from the adenine rescued from DNA and RNA
degradation in the purine nucleotide salvage pathway, an
essential route in cells unable to perform de novo synthesis of
nucleic and ribonucleic acids. These increased APRT levels agree
with the AMP accumulation detected in late disease stages of
GRACILE Syndrome in transgenicmice [31]. GNPDA1 participates
in the hexosamine biosynthetic pathway, whose end-products
will be used for making glycosaminoglycans, proteoglycans,
and glycolipids that are key structural components of cell
membranes, extracellular matrix and connecting tissues.
GNPDA1 catabolyzes the reversible conversion of D-glucos-
amine-6-phosphate into D-fructose-6-phosphate, which could
be used as a direct substrate in the glycolitic pathway possibly
at the expense of cellular structural components.
Noteworthy, the ferritin light chain (FTL) levelswere increased
in the BCS1L mutant fibroblasts. Ferritin is the primary intracel-
lular iron-storage protein complex and keeps iron in a soluble
and nontoxic state. It is composed of heavy and light ferritin
chains, and variations in its subunits compositionmay affect the
rates of iron uptake and release in human cells. Many patients
harboring mutations in the BCS1L gene present with iron
overload, increased ferritin levels and low ironbinding capacities,
and based on these clinical evidences, a role for BCS1L in iron
homeostasis was proposed [14]. Since ferritin is up-regulated in
response to different types of cellular stress [33], it is plausible to
speculate that the increased FTL levels could constitute a
secondary response to the metabolic and oxidative stresses
generated by the BCS1Lmutations.
4.2. Alterations in the regulation of gene and protein expression
The second protein group involved those participating in the
regulation of gene and protein expression, in agreementwith the
observed alterations in nucleic and amino acid metabolisms via
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cells showed reduced levels of the SND1, Lamin-A/C, XRCC6 and
DDX1 proteins. SND1 is a component of the RNA-induced
silencing complex (RISC) that plays a dual role in the regulation
of transcription and pre-mRNA splicing [34]. Lamin-A/C is a
constituent of the nuclear lamina, a protein matrix involved in
nuclear stability, chromatin structure and gene expression that
regulates cell cycle and apoptosis [35]. XRCC6 is a subunit of the
ATP-dependent DNA helicase 2, which is required for the
non-homologous end joining (NHEJ) pathway of DNA repair [36].
Alterations in this pathway may cause genomic instability and
cell cycle arrest and it is associated with several human genetic
syndromes [37]. The ATP-dependent RNA helicase DDX1 belongs
to the DEAD box protein family, implicated in a number of
cellular processes that involve the modification of RNA second-
ary structures. This protein plays an RNA clearance role at DNA
double-strand break sites, thereby facilitating the template-
guided repair of transcriptionally active regions of the genome
[38]. The BCS1L mutant fibroblasts also exhibited mildly de-
creased levels of the eukaryotic translation initiation factor
EIF3H. These cells possibly compensate for those alterations by
up-regulating other gene expression regulatory proteins, such as
cytoplasmic asparagine-tRNA ligase (NARS), the abhydrolase
domain-containing protein 14B (ABDH14B), or the heterogeneous
nuclear ribonucleoprotein Q (hnRNP Q). NARS contributes to the
initial steps of protein biosynthesis by activating and transferring
asparagine to specific tRNAmolecules. ABDH14B is an unknown
function enzyme that could be involved in activating nuclear
transcription [39]. HNRPQ is anmRNA-bindingprotein implicated
in translation regulation throughmiRNA-mediated repression of
specific mRNAs [40], as well as in cellular stress responses by
regulating p53 translation efficiency and thereby, cell cycle and
apoptosis progression [41]. In oxidative stress conditions p53 is
imported into mitochondria, where it interacts with the mito-
chondrial DNA (mtDNA) single-stranded binding protein
(mtSSB) to promote mtDNA repair [42]. In agreement, the levels
of the mtSSB protein, involved in mtDNA replication [43], were
also raised. Since increased mitochondrial proliferation is
commonly associated with respiratory chain defects, the
mtSSB protein up-regulation would enable a dual oxidative
stress-induced response, allowing for the protection of
mtDNA against oxidative damage lesions in parallel with
enhancing mitochondrial biogenesis to compensate for the
dysfunctional respiratory chain. These putative alterations
in the regulation of gene and protein expression are sugges-
tive of cell survival adaptations that could ultimately affect
cell division and apoptosis. In this regard, the BCS1L mutant
fibroblasts exhibited slow growth rates in glucose media and
apoptotic cell death [22].
4.3. Alterations in cytoskeleton formation and maintenance
In eukaryotic cells, the cytoskeleton is composed of actin
filaments, intermediate filaments and microtubules that play
important roles in the organization and distribution of the
internal cellular structures, in the intracellular transport of
organelles and secretory vesicles, and in cellular division. The
BCS1L mutant fibroblasts showed putative alterations in cyto-
skeleton formation through the reduced levels of a number of
structural constituents, such as vinculin, moesin, or the WDR1protein, which may function either as cross-linkers between
plasma membranes and actin-based cytoskeletons or are
involved in the assembly/disassembly of actin filaments, or
such as vimentin, an intermediate filament scaffolding protein
that plays a role in anchoring the organelles position in the
cytosol, or alpha-tubulin, a major structural component of the
microtubules. Cytoskeletondisorganization could thus takeplace
as a consequence of the decreased levels of its key structural
components, which could be potentially compensated by the
up-regulation of regulatory proteins involved in the organization
and assembly of these structures. Such could be the case for the
Rho GTPase activating protein p50rhoGAP (or CDC42GAP),
involved in actin cytoskeleton remodeling through the activation
of signal transduction pathways from plasma-membrane recep-
tors [44]; the dihydropyrimidinase-related protein CRMP-2, that
regulates actin cytoskeleton organization and microtubules
assembly [45]; septin-11, a cytoskeletal GTPase that associates
with cellular membranes, actin filaments and microtubules,
thus playing a role in cytoskeleton reorganization and cellular
architecture maintenance [46]; or gelsolin, a calcium-dependent
actin-binding protein that regulates actin filaments assembly
and disassembly [47]. Sincemitochondria arewell known to bind
andmove alongmicrotubules and actin filaments, a hypothetical
destructuration of the cytoskeleton could explain the predomi-
nantly fragmented phenotype of the mitochondrial network in
BCS1Lmutant fibroblasts, in the absence of significant alterations
in proteins involved in the mitochondrial fusion and fission
processes [22].
Of note, cytoskeleton constituents may act as powerful
regulatory checkpoints that directly impact mitochondrial
metabolism. For instance, dimeric tubulin physically interacts
with VDAC, a component of the major ion channel of the
mitochondrial outer membrane, to regulate respiration and
energy metabolism [48]. Most glycolytic enzymes have been
shown to bind to microtubules, and their enzyme activities
depend on the bound–unbound state [49]. By this type of control,
cytoskeleton components could selectively adapt metabolic
fluxes between mitochondria and the cytosol to alterations in
metabolic conditions, and provide a functional link between
mitochondrial metabolism, the internal cellular organization
and cell cycle.
4.4. Alterations in intracellular trafficking and
signal transduction
Complex III-deficient fibroblasts exhibited increased levels
of proteins involved in cell signaling processes that couple
gene expression to intracellular trafficking, such as the
phosphatidylethanolamine-binding protein PEPBP1/RKIP,
annexin 2, annexin 4 and sorting nexin 6 (SNX6). RKIP is a
master modulator of the MAP kinases, NF-κB and G-protein-
mediated signaling pathways to control cellular growth,motility,
apoptosis and genomic integrity [50]. Annexins are cytosolic
proteins that bind negatively charged phospholipids present in
the membrane walls in a Ca2+-dependent manner [51].
Annexin 2 (ANXA2) is a multifunctional protein that binds
PIP2 (phosphatidylinositol-4,5-bisphosphate) to facilitate actin
assembly in the vicinity of the cell membrane [52], regulates
post-transcriptional gene expression [53], and the biogene-
sis of multivesicular transport intermediates destined for late
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[54]. Annexin A4 (ANXA4) is involved in the regulation of endo-
and exocytosis, in ion-transport regulation and in the
Ca2+-dependent modulation of the NF-κB signaling pathway
[55]. SNX6 is a component of the retromer complex that
mediates the retrograde trafficking of membrane proteins
from endosomes to the trans-Golgi network (TGN), essential
for the retrieval of membrane receptors [56]. This protein links
the retromer to themicrotubule motor complex that allows the
long-range movement of endosomes from the cell periphery to
the TGN [57]. Recent proteomic analyses identified SNX6 as an
autophagosome component, suggesting a role for the retromer
complex in mTOR-dependent autophagy [58]. Decreased levels
of the COPII vesicle coat SEC24D protein were detected in the
BCS1L mutant fibroblasts. The COPII vesicle coat promotes the
anterograde transport of newly synthesized membrane pro-
teins from the endoplasmic reticulum (ER) to the TGN, where
SEC24 protein isoforms (A, B, C and D) mediate the selective
export of ER transmembrane proteins by involving lipid rafts as
early sorting platforms [59].
These observations suggest a general up-regulation of the
sorting machineries of transmembrane proteins to endosomes
and lysosomes, probably as a way to retrieve important
molecules for re-use in detriment of de novo protein synthesis,
more energy consuming, or alternatively to get rid of dysfunc-
tional organelles ormolecules thatmight otherwise accumulate
as a consequence of permanent oxidative damage. In agree-
ment, our group has recently demonstrated that BCS1Lmutant
fibroblasts show increased bulk autophagy and an accumula-
tion of vesicles, autophagic vacuoles and lysosomes as a result
of a partial blockage of the autophagic flux [60]. This could be a
consequence of the predicted cytoskeleton destructuration,
since endosomal protein sorting requires localized polymeriza-
tion of actin filaments and microtubules [57,61].
4.5. Alterations in cellular stress responses
Metabolic and oxidative stress could elicit the activation of
cellular stress responses in the BCS1L mutant fibroblasts, as
evidenced by the raised levels of ER chaperones that take part
in the Unfolded Protein Response (UPR), such as GRP78, ERP29
and ERP70. This mechanism is activated in response to the
accumulation of unfolded or misfolded proteins to restore the
normal cellular functions by halting protein translation and
activating signaling pathways that increase the expression of
molecular chaperones that target oxidized proteins for
proteasomal degradation [62]. Prolonged failure to adapt to
ER stress will result in the UPR aiming towards apoptosis,
which could explain the increased cell death observed in
BCS1L mutant fibroblasts [22].
PARK7/DJ-1 protein levels were also increased in the
mutant cells. DJ-1 plays an important protective role against
oxidative stress and cell death. Under normal conditions, DJ-1
is predominantly located in the cytoplasm and, in response to
oxidative stress, it translocates to the mitochondrion and
subsequently to the nucleus, where it acts as a redox sensitive
chaperone. Within mitochondria, it seems to cooperate with
the PINK1/parkin machinery to regulate the correct function
and morphology of the mitochondrial network and for the
autophagy of dysfunctional mitochondria [63,64]. Possibly, themetabolic and oxidative stress observed in the BCS1L mutant
fibroblasts might induce the expression of proteins with
protective roles against ROS and cell death induction. These
expression variations probably imply further alterations in
gene expression to promote cellular adaptations to metabolic
and oxidative damage.5. Conclusions
The DIGE technology has allowed us to obtain a protein profile
characteristic for fibroblasts with mutations in BCS1L. Current
evidence suggests a general defect in energy metabolism and
a shift towards anaerobic glycolysis and catabolic processes as
alternative ways to obtain ATP, and a whole cellular genetic and
metabolic reprogramming to adapt cell survival tomitochondrial
dysfunction-elicited oxidative stress. Gaining deeper insight into
these functional adaptations will pave the way towards bio-
markers detection and future therapeutic strategies for complex
III deficiency.
Supplementary data to this article can be found online at
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